头孢西丁联合阿奇霉素治疗小儿肺炎支原体肺炎的效果及安全性研究

Effect and Safety of Cefoxitin Combined with Azithromycin in the Treatment of Children with Mycoplasma Pneumoniae Pneumonia

目的探讨小儿肺炎支原体肺炎通过头孢西丁+阿奇霉素治疗的效果与安全性。方法随机选取该院2015年1月—2017年12月收治的支原体肺炎患儿83例,以不同治疗方法为差异分作两组,41例予以阿奇霉素治疗者作对照组,42例通过头孢西丁+阿奇霉素治疗者作治疗组,对比分析两组疗效及安全性。结果治疗组总有效率是97.62%,较对照组的80.49%高,差异有统计学意义(χ~2=6.298,P=0.012);治疗后,治疗组TNF-α、IL-6水平较对照组低,差异有统计学意义(t=8.359、5.858,P=0.010、0.020);两组不良反应比较差异无统计学意义(χ~2=0.131,P=0.717)。结论通过头孢西丁联合阿奇霉素对小儿肺炎支原体肺炎展开治疗效果显著,且不良反应少。

Objective To investigate the efficacy and safety of cefoxitin ＋ azithromycin in children with pneumonia my-coplasma pneumonia. Methods 83 children with mycoplasmal pneumonia admitted to the hospital from January 2015 to December 2017 were randomly selected. The difference was divided into two groups according to different treatment methods. 41 patients were treated with azithromycin as control group and 42 patients received cefoxitin ＋ Azithromycin treatment group for treatment group, comparative analysis of the efficacy and safety of the two groups. Results The total effective rate of the treatment group was 97.62%, which was higher than that of the control group,the different was statistically significant （χ^2=6.298, P=0.012）. After treatment, the levels of TNF-α and IL-6 in the treatment group were lower than those in the control group,the different was statistically significant（t=8.359,5.858,P=0.010,0.020）; the difference in adverse reactions between the two groups was not statistically significant （χ^2= 0.131, P=0.717）. Conclusion The efficacy of cefoxitin combined with azithromycin in the treatment of children with Mycoplasma pneumoniae pneumonia is significant, and the adverse reactions are few.